The scoring system may help in the design of new treatment strategies and may assist in the comparison of different studies.
Addition of assigned points. If Karnofsky Performance Scale <60, item is assigned 1 point.
Facts & Figures
- 407 patients with SCLC, seen between 1979 and 1985.
- All patients received short-term intensive regimens (cyclophosphamide, etoposide and methotrexate or ifosfamide and etoposide, both followed by thoracic irradiation if complete response was noted).
|Manchester score||Prognostic group||Two year survival (%)|
|2 - 3||Medium||2.5|
Original/Primary ReferenceCerny, T; Blair V, Anderson H et al. Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. International Journal of Cancer. 1987, (2): 146–149.
ValidationKawahara, Masaaki; Masahiro Fukuoka, Nagahiro Saijo et al. (1996). Prognostic factors and prognostic staging system for small cell lung cancer. Japanese Journal of Clinical Oncology (Oxford University Press) 27 (3): 158–165. doi:10.1093/jjco/27.3.158. PMID 9255270. ISSN: 0368-2811.
Other ReferencesMaestu, I; Pastor M, Gómez-Codina J et al. (Jun 1997). Pretreatment prognostic factors for survival in small-cell lung cancer: a new prognostic index and validation of three known prognostic indices on 341 patients .Annals of Oncology 8 (6): 547–553. doi:10.1023/A:1008212826956. PMID 9261523.Zarogoulidis P, et al. Intensive care unit and lung cancer: when should we intubate? J Thorac Dis. 2013 Sep;5 Suppl 4:S407-12. doi: 10.3978/j.issn.2072-1439.2013.08.15.
About the Creator
Thomas Cerny, MD, is chief of hematology and oncology at Kantonsspital St Gallen and also professor of medical oncology at the University of Berne. He is president of the Swiss Cancer Foundation and Oncosuisse. Dr. Cerny researches multiple types of cancer including gastrointestinal and lung cancer.
To view Dr. Thomas Cerny's publications, visit PubMed